Regeneron/Sanofi's antibody underwhelms in asthma study — shares of rival AnaptysBio pay the price
Although expectations were muted, Regeneron $REGN and Sanofi’s $SNY experimental IL-33 antibody has underwhelmed in a proof-of-concept mid-stage asthma trial. Although the drug significantly improved the loss of asthma control and lung function as a monotherapy compared to a placebo, its effect was neither superior to the established Dupixent, nor of value when combined with the IL-4/IL-13 treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.